[The Long Journey from Palpation to Biopsy : The History of Diagnosing Prostate Cancer]

Overview

Journal Urologe A

Specialty Urology

Date 2020 May 17

PMID 32415394

Authors

J Konert

L Sentker

C August

M Hatzinger

Affiliations

Soon will be listed here.

Abstract

Though it is thousands of years old, prostate cancer (PCa) has only been known for 200 years. Until about 50 years ago, the diagnosis could only be made by digital rectal examination. Although the first prostate biopsies were already implemented in the beginning of the last century, it only obtained importance with the introduction of prostate-specific antigen (PSA) testing in the early screening for PCa and the pathologist, thus, became an essential partner for the urologist. In more recent years, specific MRI has significantly increased the accuracy of prostate biopsies. Thus, the question arises whether this technique is going to be so meaningful one day that prostate biopsy and the associated pretherapeutic histology are going to be redundant.

References

Horstmann W . [Pathologic-anatomic investigations on neoplastic diseases of the prostate, especially of the carcinoma]. Z Urol. 1952; 45(1):50-9. View

GRABSTALD H . BIOPSY TECHNIQUES IN THE DIAGNOSIS OF CANCER OF THE PROSTATE. CA Cancer J Clin. 1965; 15:134-7. DOI: 10.3322/canjclin.15.3.134. View

Kraus H . [Case report on the treatment of prostate carcinoma with estrogens]. Z Urol. 1956; 49(7):403-6. View

RUPPERT H . [Histopathology of prostate cancer under hormone therapy]. Z Urol. 1953; 46(7):443-56. View

Wang M, Valenzuela L, Murphy G, Chu T . Purification of a human prostate specific antigen. Invest Urol. 1979; 17(2):159-63. View

Hoedemaeker R, Rietbergen J, Kranse R, Schroder F, van der Kwast T . Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol. 2000; 164(2):411-5. View

Luboldt H, Altwein J, Bichler K, Czaja D, Husing J, Fornara P . [Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle]. Urologe A. 1999; 38(2):114-23. DOI: 10.1007/s001200050253. View

Ablin R, SOANES W, Bronson P, Witebsky E . Precipitating antigens of the normal human prostate. J Reprod Fertil. 1970; 22(3):573-4. DOI: 10.1530/jrf.0.0220573. View

Stein B, Vangore S, PETERSEN R, Kendall A . Immunoperoxidase localization of prostate-specific antigen. Am J Surg Pathol. 1982; 6(6):553-7. DOI: 10.1097/00000478-198209000-00007. View

10.

Soula G . [Cancer of the prostate: the markers other than prostatic acid phosphatase]. Bull Cancer. 1985; 72(6):527-30. View

11.

Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D . Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001; 58(3):417-24. DOI: 10.1016/s0090-4295(01)01264-x. View

12.

Van Neste L, Hendriks R, Dijkstra S, Trooskens G, Cornel E, Jannink S . Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol. 2016; 70(5):740-748. DOI: 10.1016/j.eururo.2016.04.012. View

13.

Dijkstra S, Govers T, Hendriks R, Schalken J, Van Criekinge W, Van Neste L . Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. BJU Int. 2017; 120(5):659-665. DOI: 10.1111/bju.13861. View

14.

Hodge K, McNeal J, Terris M, Stamey T . Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989; 142(1):71-4; discussion 74-5. DOI: 10.1016/s0022-5347(17)38664-0. View

15.

Stewart C, Leibovich B, Weaver A, Lieber M . Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001; 166(1):86-91; discussion 91-2. View

16.

Andriole G . Pathology: the lottery of conventional prostate biopsy. Nat Rev Urol. 2009; 6(4):188-9. DOI: 10.1038/nrurol.2009.46. View

17.

Chun F, Epstein J, Ficarra V, Freedland S, Montironi R, Montorsi F . Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol. 2010; 58(6):851-64. DOI: 10.1016/j.eururo.2010.08.041. View

18.

Delongchamps N, de la Roza G, Jones R, Jumbelic M, Haas G . Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int. 2008; 103(1):49-54. PMC: 2701544. DOI: 10.1111/j.1464-410X.2008.07900.x. View

19.

Dhom G . Histopathology of prostate carcinoma. Diagnosis and differential diagnosis. Pathol Res Pract. 1985; 179(3):277-303. DOI: 10.1016/S0344-0338(85)80138-2. View

20.

GLEASON D . Classification of prostatic carcinomas. Cancer Chemother Rep. 1966; 50(3):125-8. View